- Khiron has successfully exported its registered cannabis
strains, in the form of live clones, from Colombia to Europe
- Company is executing on an asset light growth strategy in
Europe by working with contract
manufacturing and distribution partners to accelerate production
and delivery of EU-GMP certified medical cannabis products
- Company expects to grow its existing European offering by
introducing branded extracts and dried flower products, based on
those already distributed in Colombia and Peru, with over 13,000 prescriptions written
to date
- By 2024, the European market is expected to be worth nearly
$22bn (source: Prohibition
Partners)
TORONTO, March 11, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that the
Company has successfully exported its registered Colombian cannabis
strains, in the form of live clones, to Europe. This significant milestone represents
the first shipment of medical cannabis live plant material to
Europe from Colombia and is expected to accelerate access
to European markets as the Company executes on its asset light
growth strategy in the United
Kingdom and Germany.
Through its EU-GMP certified supply chain partners in
Europe, Khiron plans to introduce
branded, cannabis-based medicinal products based on those already
distributed by the Company in Colombia and Peru. Over the last year, more than 13,000
written prescriptions for extracts, formulated with Khiron´s
registered cannabis strains, have been issued to patients in
Latin America. As clinical
evidence mounts, safety and efficacy data arising from Khiron's
wholly-owned clinics in Latin
America is expected to serve as a cornerstone of the
Company's European medical education program.
Tejinder Virk, President of
Khiron Europe, commented: "Our experience in Colombia and Europe tells us that doctors require solid
clinical evidence to feel confident that medical cannabis is the
right treatment for their patients. By exporting our Colombian
cannabis strains, we will be able to bring our Latin American
extracts to European patients, resulting in wider choices for
doctors, and safer, more efficacious patient outcomes.
Additionally, this import provides an opportunity to accelerate
speed to market, optimize our global diversified supply chain and
maximize economics."
Khiron's vertically integrated seed-to-patient business model is
currently experiencing tremendous growth in Colombia. To date, Khiron medical cannabis
products have shown strong evidence as alternative treatments for
ailments such as chronic pain, anxiety, insomnia, depression,
epilepsy, migraines, and Parkinson's Disease. With the proof of
concept now validated in Colombia,
the Company plans to build upon its success in new markets.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru and the United
Kingdom, and is positioned to commence sales of medical
cannabis in Germany and
Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and United
Kingdom. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced and diverse executive team and Board
of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 275-8984
Media Contact:
Elsa
Navarro
Vice President, Communications
E: enavarro@khiron.ca
Khiron Europe:
Tejinder
Virk
Europe President
E: tvirk@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-becomes-first-colombian-medical-cannabis-company-to-export-live-cannabis-clones-to-europe-301245194.html
SOURCE Khiron Life Sciences Corp.